Patient choice and adherence with disease-modifying therapy in multiple sclerosis

Patient choice and adherence with disease-modifying therapy in multiple sclerosis

Bibliographic Details
Main Authors:	Burke, G, Pozo, A, Nairne, A, Birmingham, H, Gregory, R, Palace, J
Format:	Conference item
Published:	2004

Similar Items

Psychosocial predictors of patient adherence to disease-modifying therapies for multiple sclerosis
by: Alosaimi FD, et al.
Published: (2017-03-01)

SEX RATIO IN AN OXFORD BASED STUDY OF MULTIPLE SCLEROSIS PATIENTS
by: Matthews, L, et al.
Published: (2009)

Adherence to disease-modifying therapies among patients with multiple sclerosis in Bulgaria – A real world study
by: Yoana Seitaridou, et al.
Published: (2024-02-01)

Alopecia in Multiple Sclerosis Patients Treated with Disease Modifying Therapies
by: Mokshal H. Porwal, et al.
Published: (2022-06-01)

Modifying disability in progressive multiple sclerosis.
by: Palace, J, et al.
Published: (2014)

Modifying disability in progressive multiple sclerosis
by: Palace, J, et al.
Published: (2014)

The evaluation of a novel "goat serum" therapy (Aimspro) in multiple sclerosis
by: Burke, G, et al.
Published: (2005)

Treatment satisfaction with disease-modifying therapy is the only predictor of Adherence among multiple sclerosis patients from Upper Egypt
by: Eman M. Khedr, et al.
Published: (2024-03-01)

Disease Modifying Therapy in Multiple Sclerosis: Evaluation of Patients Satisfaction in Iranian Multiple Sclerosis Population
by: Negar Molazadeh, et al.
Published: (2023-01-01)

Editorial: Disease modifying therapies in multiple sclerosis
by: Simona Bonavita, et al.
Published: (2022-08-01)

Multiple sclerosis and pregnancy. Impact of multiple sclerosis disease-modifying therapy on the health of newborns
by: T. I. Yakushina
Published: (2021-02-01)

Adherence to Therapy, Physical and Mental Quality of Life in Patients with Multiple Sclerosis
by: Alessandra Buja, et al.
Published: (2021-07-01)

Personalized Use of Disease-Modifying Therapies in Multiple Sclerosis
by: Chi-Yan Lee, et al.
Published: (2024-01-01)

Safety of Newer Disease Modifying Therapies in Multiple Sclerosis
by: Georges Jalkh, et al.
Published: (2020-12-01)

The UK long-term cost-effectiveness study of disease-modifying therapies in multiple sclerosis: lessons from tire first analysis
by: Palace, J, et al.
Published: (2008)

Assessment of Thyroid Functions in Multiple Sclerosis Patients Treated with Disease Modifying Therapies
by: EIaf Dalas, et al.
Published: (2023-08-01)

Author response to comment on: Alopecia in multiple sclerosis patients treated with disease modifying therapies
by: Mokshal H. Porwal BSc, et al.
Published: (2022-09-01)

Approved and Emerging Disease Modifying Therapies on Neurodegeneration in Multiple Sclerosis
by: Madeline Bross, et al.
Published: (2020-06-01)

Escalation or high-efficacy disease-modifying therapies in multiple sclerosis
by: Elnaz Asadollahzadeh
Published: (2023-07-01)

Effect of sildenafil citrate on CBF and BOLD activation in multiple sclerosis patients
by: Manson, S, et al.
Published: (2005)

An evaluation of adherence in patients with multiple sclerosis newly initiating treatment with a self-injectable or an oral disease-modifying drug
by: Munsell M, et al.
Published: (2016-12-01)

Bioavailable central nervous system disease-modifying therapies for multiple sclerosis
by: Hans-Peter Hartung, et al.
Published: (2023-11-01)

Navigating choice in multiple sclerosis management
by: Ralf A. Linker, et al.
Published: (2019-02-01)

Preferred Features of Oral Treatments and Predictors of Non-Adherence: Two Web-Based Choice Experiments in Multiple Sclerosis Patients
by: Wicks, Paul, et al.
Published: (2015-03-01)

Impact of Disease-Modifying Therapies on Gut–Brain Axis in Multiple Sclerosis
by: Ilaria Del Negro, et al.
Published: (2023-12-01)

Persistence to disease-modifying therapies for multiple sclerosis in a Canadian cohort
by: Melesse DY, et al.
Published: (2017-06-01)

Saudi Consensus Recommendations on the Management of Multiple Sclerosis: Disease-Modifying Therapies and Management of Relapses
by: Yaser M. Al Malik, et al.
Published: (2022-12-01)

Making the diagnosis of multiple sclerosis.
by: Palace, J
Published: (2001)

Effect of sildenafil citrate (Viagra) on cerebral blood flow in patients with multiple sclerosis
by: Burke, G, et al.
Published: (2006)

Medication possession ratio: implications of using fixed and variable observation periods in assessing adherence with disease-modifying drugs in patients with multiple sclerosis
by: Kozma CM, et al.
Published: (2013-06-01)

Inhibition of Human Neutrophil Functions In Vitro by Multiple Sclerosis Disease-Modifying Therapies
by: Sara Scutera, et al.
Published: (2020-11-01)

Brain Atrophy as an Outcome of Disease-Modifying Therapy for Remitting-Relapsing Multiple Sclerosis
by: Magdalena Chylińska, et al.
Published: (2023-01-01)

Factors Associated with Therapeutic Adherence in Multiple Sclerosis in Spain
by: Soria C, et al.
Published: (2023-03-01)

Recommendations for switching patients with highly active multiple sclerosis from other disease modifying drugs for multiple sclerosis to cladribine tablets
by: N. A. Totolyan, et al.
Published: (2020-10-01)

Perspectives and experiences of Dutch multiple sclerosis patients and multiple sclerosis-specialized neurologists on injectable disease-modifying treatment
by: Visser LH, et al.
Published: (2016-04-01)

New and old treatments for multiple sclerosis.
by: Palace, J
Published: (1998)

MRI in Leber's optic neuropathy with multiple sclerosis (Harding's disease)
by: Kuker, W, et al.
Published: (2006)

The UK Multiple Sclerosis database.
by: Palace, J, et al.
Published: (1999)

Adherence to Mediterranean Diet Is Associated with Multiple Sclerosis Severity
by: Monica Guglielmetti, et al.
Published: (2023-09-01)

Monitoring response to disease-modifying treatment in multiple sclerosis
by: J. Río, et al.
Published: (2023-04-01)